Through
9/15
Penn Medicine researchers have found that knocking out a T cell’s CD5 gene greatly enhances the cell’s anticancer activity in a variety of preclinical cancer models.
For patients whose cancers don't respond to current CAR T cell therapies, a new, modified CAR T cell therapy by Penn’s Carl June shows promise in a phase 1 clinical trial.
Carl June accepted the 2024 Breakthrough Prize in Life Sciences at a Los Angeles ceremony, making him the sixth recipient from Penn.
Penn Medicine researchers have assessed the percentage of patients from minority health populations and reveal inequities in access to transformative CAR T cell therapy.
Penn Engineers have developed a novel method for manufacturing CAR T cells using lipid nanoparticles as delivery vehicles.
Immunological imprinting from the original ancestral SARS-CoV-2 strain has a significant impact on the antibody responses to the variants and boosters based on them.
Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer.
Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors.
Four of Penn’s Breakthrough Prize recipients, Carl June, Katalin Karikó, Virginia M-Y Lee, and Drew Weissman, were honored at a reception on Feb. 13.
A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more.
John V. Bosso of the Perelman School of Medicine says that sneezing helps clear the nose of irritants, dirt, allergens, viruses, and bacteria.
FULL STORY →
Scott Hensley of the Perelman School of Medicine says that the bird flu virus would have to change significantly to be able to bind effectively to human cells.
FULL STORY →
A paper by Katelyn A. Walzer and Boris Striepen of the School of Veterinary Medicine reveals the gene expression of the parasite cryptosporidium across its life cycle.
FULL STORY →
Researchers led by Scott Hensley of the Perelman School of Medicine have collaborated with Drew Weissman to develop an mRNA vaccine to treat the H5N1 avian flu.
FULL STORY →
Researchers at Penn Medicine have created a human bird flu vaccine using mRNA, the same platform as the COVID-19 vaccine.
FULL STORY →
Researchers led by Scott Hensley of the Perelman School of Medicine are developing an mRNA vaccine for the H5N1 avian flu with support from Nobel Prize cowinner Drew Weissman.
FULL STORY →